Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...
Strategy for enhancing immune cell infiltration could be combined with other methods to improve cell-based immunotherapies ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...
Investigators said the unique features of chimeric antigen receptor (CAR) T-cell therapy may warrant novel approaches to cost ...
Nektar Therapeutics said that a phase 1 study examining a combination of NKTR-255 in combination with an autologous ...
Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and ...
An online survey-based cross-sectional study assessed current practice patterns on the management of post-CAR-T failure in patients with relapsed or refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback